Impact of phosphoproteomics in the translation of kinase‐targeted therapies

Signaling pathways driven by protein and lipid kinases are altered in most human diseases. Therefore, pharmacological inhibitors of cell signaling are one of the most intensively pursued therapeutic approaches for the treatment of diseases such as cancer, neurodegeneration, and metabolic syndromes....

Full description

Saved in:
Bibliographic Details
Published in:Proteomics (Weinheim) 2017-03, Vol.17 (6), p.np-n/a
Main Authors: Casado, Pedro, Hijazi, Maruan, Britton, David, Cutillas, Pedro R.
Format: Article
Language:English
Subjects:
Animals
Bioinformatics
Biomarkers
Cancer
Circuits
Enzyme inhibitors
Humans
Inhibitors
Kinase inhibitors
Kinases
Medical treatment
Metabolic disorders
Molecular Targeted Therapy
Neurodegeneration
Pharmacology
Phosphoproteins - metabolism
Phosphoproteomics
Protein Kinase Inhibitors - pharmacology
Protein Kinases - metabolism
Proteomics - methods
Signal transduction
Signaling
Target recognition
Technology
Translational Research, Biomedical
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Signaling pathways driven by protein and lipid kinases are altered in most human diseases. Therefore, pharmacological inhibitors of cell signaling are one of the most intensively pursued therapeutic approaches for the treatment of diseases such as cancer, neurodegeneration, and metabolic syndromes. Phosphoproteomics is a technique that measures the products of kinase activities and, with the appropriate bioinformatics techniques, the methodology can also provide measures of kinase pathway activation and network circuitry. Hence, due to recent technological advantages, LC‐MS‐based quantitative phosphoproteomics provides relevant information for the design and implementation of kinase inhibitor based therapies. Here, we review how phosphoproteome profiling is being used in translational research as a means to identify drug targets and biomarkers for personalizing therapies based on kinase inhibitors.
ISSN:1615-9853
1615-9861
DOI:10.1002/pmic.201600235